We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+27.83%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$130M
AUM Growth
+$3.84M
Cap. Flow
-$22.7M
Cap. Flow %
-17.42%
Top 10 Hldgs %
57.06%
Holding
85
New
22
Increased
8
Reduced
24
Closed
13

Top Buys

Rank Stock Value
1
AGTC
Applied Genetic Technologies Corporation
AGTC
+$2.44M
2
ZSPH
ZS PHARMA INC COMS TK (DE)
ZSPH
+$1.79M
3
OTIC
Otonomy, Inc.
OTIC
+$1.71M
4
ASND icon
Ascendis Pharma A/S
ASND
+$1.7M
5
ZGNX
Zogenix, Inc.
ZGNX
+$1.21M

Top Sells

Rank Stock Value
1
PCYC
PHARMACYCLICS INC
PCYC
+$7.59M
2
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$4.31M
3
OCRX
Ocera Therapeutics, Inc.
OCRX
+$4.04M
4
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$3.36M
5
NVDQ
Novadaq Technologies Inc.
NVDQ
+$2.4M

Sector Composition

Rank Sector Weight
1 Healthcare 55.65%
2 Financials 0.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZGNX
26
DELISTED
Zogenix, Inc.
ZGNX
$1.17M 0.9%
+106,713
New +$1.21M
ELOS
27
DELISTED
Syneron Medical Ltd
ELOS
$1.13M 0.86%
90,947
– –
CYTR
28
DELISTED
CytRx Corp
CYTR
$1.01M 0.78%
50,136
-7,597
-13% -$141K
BLUE
29
DELISTED
bluebird bio
BLUE
$966K 0.74%
618
-347
-36% -$458K
TNDM icon
30
Tandem Diabetes Care
TNDM
$1.34B
$963K 0.74%
+7,634
New +$993K
JNJ icon
31
Johnson & Johnson
JNJ
$618B
$946K 0.73%
9,400
– –
CRDC
32
DELISTED
CARDICA INC COM NEW (DE)
CRDC
$936K 0.72%
148,600
– –
ECI
33
DELISTED
ENCISION INC
ECI
$829K 0.64%
1,062,500
– –
XNPT
34
DELISTED
XENOPORT, INC.
XNPT
$828K 0.64%
116,259
+18,069
+18% +$140K
EXAC
35
DELISTED
Exactech Inc
EXAC
$811K 0.62%
31,636
– –
QURE icon
36
uniQure
QURE
$3.03B
$730K 0.56%
30,000
-9,656
-24% -$211K
CRIS icon
37
Curis
CRIS
$9.78M
$720K 0.55%
+150
New +$724K
CDNA icon
38
CareDx
CDNA
$2.26B
$687K 0.53%
123,883
+36,583
+42% +$241K
MBAI
39
Check-Cap
MBAI
$8.19M
$605K 0.46%
+458
New +$622K
ICPT
40
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$564K 0.43%
2,000
-19,900
-91% -$4.31M
NERV icon
41
Minerva Neurosciences
NERV
$185M
$507K 0.39%
+12,665
New +$524K
KERX
42
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$443K 0.34%
+34,800
New +$447K
SRGA
43
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$424K 0.33%
2,864
– –
AFMD
44
DELISTED
Affimed
AFMD
$394K 0.3%
6,250
-5,750
-48% -$356K
EPZM
45
DELISTED
Epizyme, Inc
EPZM
$376K 0.29%
+20,000
New +$413K
LMNS
46
DELISTED
LUMENIS LTD CL B ORD SHS (ISR)
LMNS
$372K 0.29%
31,072
– –
ALDX icon
47
Aldeyra Therapeutics
ALDX
$92.9M
$356K 0.27%
+35,000
New +$357K
RXII
48
DELISTED
GALENA BIOPHARMA INC COM
RXII
$348K 0.27%
+250,000
New +$348K
RIOT icon
49
Riot Platforms
RIOT
$7.63B
$305K 0.23%
82,250
– –
CUTR
50
DELISTED
Cutera, Inc.
CUTR
$303K 0.23%
23,490
-65,204
-74% -$850K
1
2
3 4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
STCG
Speece Thorson Capital Group Minnetonka, Minnesota $439M AUM 10.15% 1-Year Est. Return
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
WAS
Winch Advisory Services Appleton, Wisconsin $438M AUM 17.59% 1-Year Est. Return

DAFNA Capital Management's Q1 2015 Portfolio in Review

As of Q1 2015, DAFNA Capital Management held 85 positions worth $130M, up 3% from $126M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

DAFNA Capital Management withdrew a net $22.7M in Q1 2015, closing 13 positions and reducing 24 holdings. Its most notable exit was Ocera Therapeutics, Inc., an estimated $4.04M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 56% of assets, down from 60% a quarter earlier, followed by Financials.

Against the trend, DAFNA Capital Management opened a new position in Applied Genetic Technologies Corporation worth $2.19M.

  • DAFNA Capital Management's largest Q1 2015 buy was Applied Genetic Technologies Corporation: 109,323 shares worth $2.19M.
  • DAFNA Capital Management added most to Rigel Pharmaceuticals in Q1 2015, an estimated $989K increase.
  • DAFNA Capital Management's biggest Q1 2015 reduction was PHARMACYCLICS INC, cutting an estimated $7.59M.
  • DAFNA Capital Management fully exited Ocera Therapeutics, Inc. in Q1 2015, selling an estimated $4.04M.
  • DAFNA Capital Management's ten largest holdings make up 57% of its $130M portfolio in Q1 2015.
  • DAFNA Capital Management opened 22 new positions and closed 13 in Q1 2015.
  • DAFNA Capital Management's portfolio value rose 3% quarter-over-quarter to $130M.

Based on DAFNA Capital Management's 13F filing for Q1 2015, filed 15 May 2015.